Immunoglobulin replacement for secondary immunodeficiency after B-cell targeted therapies in autoimmune rheumatic disease: systematic literature review

Authors: Dr Sonali Wijetilleka¹, Dr Chetan Mukhtyar², Professor David Jayne³, Professor Aftab Ala⁴, Dr Philip Bright⁵, Dr Hector Chinoy⁶, Professor Lorraine Harper⁷, Dr Majid Kazmi⁸, Dr Sorena Kiani-Alikhan⁹, Dr Charles Li¹⁰, Dr Siraj Misbah¹¹, Dr Louise Oni¹², Dr Fiona Price-Kuehne¹³, Professor Alan Salama¹⁴, Miss Sarita Workman¹⁵, Dr David Wrench⁸, Dr Mohammed Yousuf Karim^{1,16}.

Author affiliations

Dr Sonali Wijetilleka, MBBS BSc, Department of Immunology ¹Frimley Health NHS Foundation Trust, Portsmouth Rd, Frimley, UK. Email address: sonaliwijetilleka@doctors.org.uk

Dr Chetan Mukhtyar MSc MD FRCP ²Department of Rheumatology, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, Norfolk, UK. Email address: chetan.mukhtyar@nnuh.nhs.uk

Professor David R Jayne MD FRCP FMedSci ³Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge, UK. Email address: dj106@cam.ac.uk

Professor Aftab Ala MD PhD FRCP

⁴Department of Gastroenterology and Hepatology, Royal Surrey County Hospital, Guildford, UK. Department of Clinical and Experimental Medicine, University of Surrey, Guildford, UK. Email address: aftabala@nhs.net

Dr Philip Bright FRCPath MSc ⁵Department of Immunology, North Bristol NHS Trust, Bristol, UK. Email address: phil.bright@nhs.net

Dr Hector Chinoy PhD FRCP ⁶Department of Rheumatology, Salford Royal NHS Foundation Trust, Manchester Academic Health Science Centre, Salford, UK. Email address: Hector.Chinoy@manchester.ac.uk

Professor Lorraine Harper PhD FRCP ⁷Department of Nephrology, Institute of Clinical Sciences, College of Medical and Dental Science, University of Birmingham, Birmingham, UK. Email address: l.harper@bham.ac.uk

Dr Majid Kazmi FRCP FRCPath ⁸Department of Haematology, Guy's and St Thomas' NHS Foundation Trust, London, UK. Email address: majid.kazmi@gstt.nhs.uk

Dr Sorena Kiani-Alikhan PhD FRCP FRCPath ⁹Department of Immunology, Barts and The London NHS Trust, London, UK. Email address: skiani@nhs.net

Dr Charles Li PhD FRCP

¹⁰Department of Rheumatology, Royal Surrey County Hospital, Guildford, UK. Email address: charles.li@nhs.net

Dr Siraj Misbah MSc FRCP FRCPath ¹¹Department of Immunology, Oxford University Hospitals, Oxford, UK. Email address: siraj.misbah@ouh.nhs.uk

Dr Louise Oni MBChB MRCPCH MA PhD, ¹²Department of Paediatric Nephrology, Alder Hey Children's NHS Foundation Trust Hospital, Liverpool, UK. Email address: Louise.Oni@liverpool.ac.uk

Dr Fiona Price-Kuehne MBBS BSc ¹³Department of Paediatrics, University of Cambridge School of Clinical Medicine, Cambridge, UK. Email address: fep30@cam.ac.uk

Professor Alan Salama PhD FRCP ¹⁴Department of Nephrology, University College London Centre for Nephrology, Royal Free Hospital, London, UK. Email address: a.salama@ucl.ac.uk

Miss Sarita Workman, MSc Registered Nurse ¹⁵Department of Immunology, Royal Free London NHS Foundation Trust, London, UK. Email address: sarita.workman@nhs.net

Dr David Wrench PhD MRCP ⁸Department of Haematology, Guy's and St Thomas' NHS Foundation Trust, London, UK. Email address: david.wrench@gstt.nhs.uk

Dr Mohammed Yousuf Karim, MSc FRCP FRCPath ¹Department of Clinical Immunology and Allergy, Frimley Park Hospital, Frimley, UK. Present address ¹⁶Department of Pathology, Sidra Medicine, Doha, Qatar. Email address: youshimmi@gmail.com

Corresponding author for manuscript:

Dr Sonali Wijetilleka, sonaliwijetilleka@doctors.org.uk, Department of Immunology, Frimley Health NHS Foundation Trust, Portsmouth Rd, Frimley, UK, GU16 7UJ. Tel: +447763051106.

Corresponding author post publication:

Dr Mohammed Yousuf Karim, <u>youshimmi@gmail.com</u>, Department of Clinical Immunology and Allergy, Frimley Park Hospital, Frimley, UK. Present address: Department of Pathology, Sidra Medicine, Doha, Qatar. Tel: +97477946782.

A declaration of all sources of funding for the research reported in the manuscript: Dr Wijetilleka was funded by an unrestricted grant from Roche Pharmaceuticals. YK, CM and DRJ were co-applicants on that grant.

Disclosures

DRJ has received research grants from Roche/Genentech. HC has received advisory board/lecture fees from Lilly, UCB, Janssen, has carried out consultancy work for Novartis, Momenta, received travel

grants from Abbvie, Janssen, and educational grants from UCB and MedImmune. LH performs ongoing consultancy work with Chemocentryx. S.Workman reports grants outside the submitted work from CSL Behring, personal fees from Biotest, other from Grifols, other from Biotest, other from LFB, other from Octapharma, other from CSL Behring, other from Jeffery Modell Foundation. The remaining authors declare they have no conflicts of interest.

Referees

Dr Savino Sciascia, Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases, Coordinating Center of Piemonte and Valle d'Aosta Network for Rare Diseases, S. Giovanni Bosco Hospital, Turin, Italy and Università degli Studi di Torino. Email: savino.sciascia@unito.it

Dr Smita Patel, Department of Immunology, Oxford University Hospitals, Oxford, UK. Email: smitapatel6@nhs.net

Dr Amolak Bansal, Department of Immunology, Epsom & St Helier University Hospitals, Epsom, UK. Email: amolak.bansal@nhs.net

Abstract:

Background: Consensus guidelines are not available for the use of immunoglobulin replacement therapy (IGRT) in patients developing iatrogenic secondary antibody deficiency following B-cell targeted therapy (BCTT) in autoimmune rheumatic disease.

Objectives: To evaluate the role of IGRT to manage hypogammaglobulinemia following BCTT in autoimmune rheumatic disease (AIRD).

Methods: Using an agreed search string we performed a systematic literature search on Medline with Pubmed as vendor. We limited the search to English language papers with abstracts published over the last 10 years. Abstracts were screened for original data regarding hypogammaglobulinemia following BCTT and the use of IGRT for hypogammaglobulinemia following BCTT. We also searched current recommendations from national/international organisations including British Society for Rheumatology, UK Department of Health, American College of Rheumatology, and American Academy of Asthma, Allergy and Immunology.

Results: 222 abstracts were identified. Eight papers had original relevant data that met our search criteria. These studies were largely retrospective cohort studies with small patient numbers receiving IGRT. The literature highlights the induction of a sustained antibody deficiency, risk factors for hypogammaglobulinemia after BCTT including low baseline serum IgG levels, how to monitor patients for the development of hypogammaglobulinemia and the limited evidence available on intervention thresholds for commencing IGRT.

Conclusion: The benefit of BCTT needs to be balanced against the risk of inducing a sustained secondary antibody deficiency. Consensus guidelines would be useful to enable appropriate assessment prior to and following BCTT in preventing and diagnosing hypogammaglobulinemia. Definitions for symptomatic hypogammaglobulinemia, intervention thresholds and treatment targets for IGRT, and its cost-effectiveness are required.

Keywords: rituximab, anti-CD20, vasculitis, ANCA, hypogammaglobulinemia, infection

Abbreviations: AIRD = autoimmune rheumatic disease, **AAV** = ANCA-associated vasculitis, BCTT= Bcell targeted therapy, DoH = Department of Health, EULAR = European League Against Rheumatism, GPA = granulomatosis with polyangiitis, **IGRT=** immunoglobulin replacement therapy, RA = Rheumatoid arthritis, SLR = systematic literature review, SPUR = serious, persistent, unusual or recurrent, UK= United Kingdom

Take home messages

- 1. Immunoglobulin replacement therapy for secondary hypogammaglobulinemia is increasing, due to B-cell targeted therapy use in autoimmune rheumatic diseases. There are no consensus guidelines available for immunoglobulin replacement in this population.
- 2. This review highlights the currently available literature, including risk factors for hypogammaglobulinemia after B-cell targeted therapy, how to monitor for development of hypogammaglobulinemia, and intervention thresholds for commencing immunoglobulin replacement.
- 3. The need for consensus guidelines is highlighted for the appropriate assessment to prevent and to diagnose hypogammaglobulinemia early, and to optimize the management of immunoglobulin replacement therapy in this group.

1. Introduction

Primary immunodeficiency (PID) is due to inherited or sporadic genetic mutation(s), and may have unknown environmental cofactors, but no other known cause [1,2]. Secondary immunodeficiency (SID) may occur consequent to disease or effects of drugs or therapies [3,4]. Immunoglobulin replacement therapy (IGRT) for drug-related secondary hypogammaglobulinemia is increasing, due to the use of B-cell targeted therapies (BCTT) for management of autoimmune rheumatic diseases (AIRD) and B-cell lymphoproliferative disease. Hypogammaglobulinemia is characterised by reduction in circulating immunoglobulins (Ig) and can predispose to severe and recurrent infections [6]. Underlying immune dysfunction and prolonged immunosuppressive drug use result in patients being at greater risk of infection, a major cause of morbidity and mortality in this population [3].


BCTT are effective treatments, but concerns remain over the long-term effects on humoral immunity with potential development of hypogammaglobulinemia and increased risk of infection [7, 8, 9, 10].


CD20+ B-cells are depleted by rituximab on average for 6–12 months, though there is substantial variability with longer periods of depletion observed in ANCA-associated vasculitis (AAV) [7]. Mature plasma cells do not express CD20 and are the source of 95% of circulating immunoglobulin G (IgG) [7]. Most patients do not have residual immune dysfunction as B-cell numbers typically recover, and early reports suggested no major effect on serum immunoglobulins [11, 12]. Hypogammaglobulinemia and associated infection risks are thought to be secondary to prolonged depletion of plasma cell precursors, which may contribute to reduced replenishment of mature plasma cells [7, 13]. There is limited data on the frequency of IGRT for rituximab-associated hypogammaglobulinemia, ranging from 6.6% in lymphoma to 14 -21% in systemic vasculitis [14]. Reports also are found in immune thrombocytopenia treated with BCTT [15].

Currently consensus guidelines are not available for the use of IGRT in patients developing iatrogenic secondary antibody deficiency following either BCTT or other immunosuppressive therapies in AIRD. This review evaluates the current literature in adults to aid diagnostic and therapeutic decision making for clinicians. We have not addressed the paediatric literature; however, the information may be of interest to paediatricians managing AIRD patients.

2. Methods

This systematic literature review (SLR) was performed in accordance with the Scottish Intercollegiate Guidelines Network (SIGN) methodology [16]. The search topics included in the SLR were identified through a Delphi process. We used the following search string on 1st September 2018- "(Immunologic Deficiency Syndromes"[Mesh] NOT "HIV Infections"[Mesh]) AND (("Antibodies, Monoclonal"[Mesh] OR "Abatacept"[Mesh] OR "TACI receptor-IgG Fc fragment fusion protein"[Supplementary Concept]) OR ("Immunoglobulin G/administration and dosage"[Mesh] AND "Immunoglobulin G/therapeutic use"[Mesh])) NOT ("case reports"[pt] OR "Review"[pt])". The results were limited by using the filters 'abstracts' 'English language' and 'published in last 10 years'. Of the 222 papers identified, data was harvested from 8 original articles. SIGN checklist screening of each article was performed prior to inclusion. Data from the current publications produced by national/international organisations were also reviewed, and the reference lists hand searched. These included: British Society for Rheumatology, UK Department of Health, European League Against Rheumatism, European Society for Immunodeficiencies, American College of Rheumatology, and American Academy of Allergy, Asthma, & Immunology, yielding a further 11 publications (Figure 1).





3. Results

3.1 Distinction between purely numerical hypogammaglobulinemia and symptomatic hypogammaglobulinemia

The current literature provides no definition to differentiate purely numerical from symptomatic hypogammaglobulinemia. Studies included in this review defined hypogammaglobulinemia at varying levels of <4 to <7.5 g/L [Table 1]. The lower limit of the normal range may vary depending on age,

population, and the particular assay [8]. Specific cut-off IgG levels necessitating IGRT are unclear. Many patients are asymptomatic with low IgG levels and IgG levels may recover following BCTT. In one series of 243 patients with systemic autoimmune disease who received rituximab, 26% developed moderate (defined as 3-4.9 g/L) or severe (< 3 g/L) hypogammaglobulinemia. This was often transient and improved spontaneously in approximately 50% of cases [8]. This study reported IgG levels in patients who develop hypogammaglobulinemia within 6 months of the first rituximab dose may recover spontaneously without use of IGRT [8]. Hypogammaglobulinemia at the initiation of rituximab treatment is suspected to be multifactorial, such as due to active disease or other treatments, and may be transient. However later onset hypogammaglobulinemia after rituximab is considered more likely to be sustained, and related to prolonged B-cell depletion [8]. As by far the dominant BCTT agent in clinical use is rituximab, the available data are concentrated on this medication, with no data available for other depleting BCTT such as ocrelizumab in AIRD.

In an 11-year study incorporating 3595 rituximab-treated patients with rheumatoid arthritis (RA), 143/3595 (4%) developed IgG below the reference range for at least 4 months [17]. Interestingly, in patients who developed low IgG, serious infection rates were higher than patients who never developed low IgG and higher than the all-exposure population, both before and after development of low IgG levels. The author surmised these patients might have an intrinsically higher infection inherent risk.

Study	Design	Number of patients	AIRD	RTX dosage and other	Other immunosuppression	Immunoglobulin levels	IGRT used No. of patients
Roberts et al. 2015 [8]	Retrospective study	243	GPA/MPA/ EGPA/SLE/ Other	Median 6g	Prior CYC 6g and glucocorticoids. Variable prior exposure to other DMARDs	lgG mild 5-6.9 g/L, moderate 3-4.9 g/L and severe <3 g/L	12
Roberts et al. 2015 [14]	Case series: subset from Roberts et al. 2014	12	GPA/MPA/ EGPA/SLE/ Other	Median 6g	Prior CYC 6g and glucocorticoids. Variable prior exposure to other DMARDs	IgG mild 5-6.9 g/L, moderate 3-4.9 g/L and severe <3 g/L	12 (10/12 SLE)
Cortazar et al. 2017 [18]	Retrospective evaluation	229	AAV	Induction therapy: combinati CYC, and high-dose steroids. Maintenance therapy: RTX w prednisone		Significant hypogammaglobulinemia, IgG<4g/L.	5 (maintenanc e group)
Gottenberg et al. 2010 [21]	Cohort study	1303	RA	416 patients treated with RTX alone and 821 patients treated with RTX plus a nonbiologic DMARD.	Prior anti-TNF and DMARDS. Pre- medication corticosteroids in 1004 patients.	Hypogammaglobulinemia IgG<6 g/L	-
Makatsori et al. 2014 [32]	Retrospective review Case series from audit of 114	19	4 RA 2 SLE 13 other (haematological)	Not specified	Yes but not specified	Hypogammaglobulinemia IgG≤4g/L.	18
Besada et al 2014 [20]	Cohort study	29	GPA	Median cumulative dose 9g after RTX initiation.	Prior CYC, concurrent prednisolone and other immunosuppression	Hypogammaglobulinemia <6 g/L	5
Marco et al. 2014 (7)	Retrospective review	177	Primary systemic vasculitis/ GPA/MPA/EGPA/ SLE/ Behcet's disease/ HSP	Median 5.9g	CYC,MMF,HCQ,AZA, MTX, 5% other	Mild (IgG 5–5.9 g/L), moderate (3–4.9 g/L) and severe (<3 g/L).	6
Venhoff et al. 2014 [22]	Retrospective analysis	37	GPA/MPA	RTX induction regimens : 2 infusions of 0.5 g each in 7 patients and 1 g each in 30 patients.	RTX induction therapy, followed by maintenance with DMARDs. Previous CYC in 92%.	Hypogammaglobulinemia IgG<5g/L	-

Table 1: Summary table of studies in systematic literature review

CYC = cyclophosphamide, RTX = rituximab, CTD =connective tissue disease RA= rheumatoid arthritis, GPA = Granulomatosis with Polyangiitis, MPA = microscopic polyangiitis, AAV= ANCA-associated vasculitis, EGPA = Eosinophilic Granulomatosis with Polyangiitis, SLE = systemic lupus erythematosus, HSP = Henoch-Schonlein purpura, TNF= tumor necrosis factor, DMARD = Disease-modifying anti-rheumatic drugs, AZA =azathioprine, MMF= mycophenolate mofetil, MTX = methotrexate, LEF = leflunomide, HCQ = hydroxychloroquine, SIE = serious infection events.

3.2 Identification of risk factors for the development of numerical or symptomatic hypogammaglobulinemia

The identification of patients at risk of hypogammaglobulinemia can help reduce associated infectionrelated morbidity. A low IgG prior to rituximab treatment is a predictor of sustained hypogammaglobulinemia, highlighted in several 3 studies [8, 14, 18]. The other possible risk factors are cumulative cyclophosphamide dose prior to rituximab therapy and use of other immunosuppressive agents [7, 19,20].

Cortazar *et al* reported that baseline IgG level at the start of maintenance therapy for AAV was the only factor associated with subsequently developing 'significant' hypogammaglobulinemia, defined as IgG <4 g/L, during maintenance rituximab therapy (HR 0.25 per 0.5 g/L increase in IgG level [95% CI 0.11, 0.56]; p= 0.001) [18]. Only patients with baseline maintenance IgG in the lowest quartile (4.08– 5.59 g/L) were noted to develop hypogammaglobulinemia. However, 82% of patients in the lowest baseline IgG quartile maintained IgG >4 g/L during continuous maintenance rituximab therapy. Neither time since initial AAV diagnosis, nor duration of B-cell depletion before onset of maintenance BCTT was associated with future hypogammaglobulinemia. The stability of IgG levels was independent of repeated rituximab doses. This was suggested to be due to a long-lived plasma cell population resistant to immunosuppressive agents and able to maintain the IgG pool. Increasing age [adjusted incident rate ratio {IRR}= 1.46 (95% CI 1.19, 1.78) p<0.001] and baseline maintenance IgG < 4 g/L [adjusted IRR= 2.13 (95% CI 1.04, 4.36) p= 0.04] were associated with developing a serious infection during maintenance therapy [18].

In granulomatosis with polyangiitis (GPA), the largest reduction in immunoglobulin levels occurred after remission induction with rituximab [20]. Subsequent maintenance therapy increased the risk of discontinuation due to hypogammaglobulinemia (HR 8.4, 95% CI 1.14 – 63, p= 0.037) [20]. Cumulative rituximab dose did not influence immunoglobulin levels, in contrast to cumulative cyclophosphamide [20]. Cumulative cyclophosphamide dose of 10g increased the risk of discontinuing rituximab due to hypogammaglobulinemia (HR 1.14 95% CI 1.01- 1.3 p= 0.034), suggesting a synergistic effect of cyclophosphamide and rituximab on B-cells in GPA patients [20]. Cyclophosphamide-associated hypogammaglobulinemia pre-rituximab may increase the risk of hypogammaglobulinemia during long-term maintenance. Of the variability in the IgG level during rituximab maintenance, 40% was reported to have been due to patient age, total cyclophosphamide cumulative dose (R² = 0.107, p = 0.047) or baseline IgG (R² = 0.179, p = 0.013) [20]. Roberts *et al* noted a weak association between prior cyclophosphamide exposure and nadir IgG concentration (Spearman r = -0.1364, p = 0.035), but no association with cumulative rituximab dose [8].

In another study of 177 patients with multisystem autoimmune disease treated with rituximab, baseline IgG levels were lower in patients who had received prior cyclophosphamide treatment (69% of patients) at the time of the first rituximab dose [(8.85 g/L vs. 10.4 g/L) (p = 0.025)], but not at 60 months [(7.9 g/L vs. 9.7 g/L) (p=0.138) (N=51)]. No association between prior cyclophosphamide exposure and development of hypogammaglobulinemia during rituximab therapy was seen. Higher cumulative corticosteroid exposure during follow-up was associated with hypogammaglobulinemia. A reduction in severe infection rates over the study period was noted with minimisation of corticosteroids and avoidance of concomitant immunosuppression. There was no association between diagnosis and development of hypogammaglobulinemia (Chi-square = 3.24; df = 2; p = 0.198). The authors concluded that transient mild to moderate hypogammaglobulinemia or occasional severe

hypogammaglobulinemia observed with repeat rituximab dosing were not dominant factors in infection risk, provided careful monitoring with judicious use of prophylactic therapies occurred [7].

Results from Gottenberg *et al* showed that low IgG <6g/L before initiation of rituximab treatment (OR 4.9 [95% CI 1.6–15.2], p = 0.005) was independently associated with higher risk of severe infection in the year following rituximab administration in RA patients. Six of 29 patients (20.7%) with low baseline IgG subsequently developed a severe infection, compared with 31/605 patients (5.1%) with normal baseline IgG [21].

3.3 Monitoring for the development of hypogammaglobulinemia

There are no specific biomarkers which are proven to guide rituximab treatment, though flow cytometry measurements of CD19+ B-cells are often performed [22]. Early recognition of hypogammaglobulinemia in BCTT-treated patients is important to prevent infection-associated morbidity. Cortazar *et al* concluded that immunoglobulin levels fall more rapidly during induction than in maintenance therapy. IgG levels declined at a mean rate of 6% per month (95% CI 4, 8%) during induction therapy [(52% per year when standardized to a common time unit (95% CI 39, 61%)]. During maintenance, IgG levels fell by a mean of 0.6% per year (95% CI -0.2, 1.4%) [18].

In patients with multisystem autoimmune disease, Marco *et al* observed that following rituximab treatment, 61/177 patients (34%) had hypogammaglobulinemia for at least 3 consecutive months during follow-up (10% mild [IgG 5-5.9 g/L], 20% moderate [IgG 3-4.9] and 4% severe [IgG<3]). Excluding those with hypogammaglobulinemia at baseline, the median time to numerical hypogammaglobulinemia was 18 months (range 1–65 months) and it took 35 months to develop maximum severity hypogammaglobulinemia (range 1–70 months) [7].

For AAV, current EULAR guidelines recommend testing serum immunoglobulin levels prior to each course of rituximab and in patients who develop recurrent infection [23]. Involvement of a clinical immunologist is recommended in patients who develop persistent hypogammaglobulinemia [23]. BSR guidelines for rituximab in RA recommend immunoglobulin levels should be checked prior to commencing therapy, 4–6 months after infusions and before re-treatment [24]. The AAAAI note the importance of checking baseline immune function in AIRD patients started on rituximab [25]. Checking baseline immunoglobulins may also assist in distinguishing drug-induced hypogammaglobulinemia from uncovering of undiagnosed PID such as common variable immunodeficiency [25].

3.4 Intervention thresholds for commencing IGRT

The United Kingdom (UK) DoH guidelines recommend initiating IGRT in patients with secondary hypogammaglobulinemia of any cause (IgG < 5 g/L) provided there is demonstrable functional antibody deficiency¹ and antibiotic prophylaxis for a period of 3 months is unsuccessful in preventing infections [26]. Currently there is no evidence base for the use of prophylactic antibiotics in drug-induced secondary hypogammaglobulinemia. In this group of patients there are no controlled trials of antibiotic prophylaxis versus IGRT. There is an unresolved debate regarding the benefits of IGRT, when considered against its costs and risks, as opposed to long-term antibiotic prophylaxis, which is cheaper but with attendant risks of microbial resistance.

¹ Functional antibody deficiency refers to failure of antibody response to polysaccharide antigens such as pneumococcus (measured as response to the unconjugated polysaccharide vaccine, rather than the conjugate vaccine)

In a case series of 12 patients (10 with vasculitis), the threshold for commencing IGRT was either moderate hypogammaglobulinemia (IgG<5g/L) or severe (<3 g/L), plus recurrent or persistent infections despite antimicrobial prophylaxis and functional antibody deficiency [14]. IGRT was initiated as per DoH guidelines and titrated dependent on infection rate and IgG levels [14]. A minimum trough IgG concentration of 8-10 g/L was used, similar to treatment guidelines for common variable immunodeficiency. An overall reduction in the frequency and severity of infections following commencement of IGRT was described [14].

Cortazar *et al* noted during maintenance therapy with BCTT, median IgG level was 4.08 g/L at initiation of IGRT for the 5 patients requiring IGRT for recurrent infections [18]. Marco *et al.* reported IGRT was used in patients with infections despite antibiotic prophylaxis and moderate or severe hypogammaglobulinemia (IgG < 5 g/l) [7].

Currently there is no agreement on a particular threshold level of IgG for intervention with IGRT in AIRD.

3.5 Initiation and administration of IGRT

Although there are no specific guidelines for the management of drug-induced hypogammaglobulinemia in AIRD, the principles of management are essentially the same as that for secondary antibody deficiency associated with B-cell lymphoproliferative disease.

The decision to start IGRT should involve the patient, clinical immunologist and the patient's autoimmune disease physician. DoH clinical guidelines for all causes of secondary antibody deficiency recommend immunoglobulin initially dosed at 0.4/kg/month [26]. The dose should be titrated to achieve an IgG trough level within the reference range, to achieve a significant reduction in the burden of bacterial infections. Evidence from IGRT in PID suggests that this approach is likely to optimise patient care [27]. Target trough IgG levels should be adjusted on an individual basis, and may be higher in patients with complications such as bronchiectasis [27]. Both intravenous and subcutaneous routes of administration should be considered [26].

Sustained hypogammaglobulinemia is reported to occur in a minority of patients after rituximab treatment, who may require long-term IGRT. In the largest study where data is available, 12/243 (4.2%) patients with a range of AIRD required IGRT [14, 25]. In an AAV study, 7/55 (21%) patients treated with cyclophosphamide followed by rituximab required IGRT [19]. The decision to discontinue rituximab can be considered in patients with an IgG < 5 g/I, with a downward trajectory and recurrent infections [7]. This decision should be balanced against ongoing disease activity, the benefit derived from rituximab treatment and the availability of alternative therapeutic options [7].

3.6 Hypogammaglobulinemia with other immunosuppressive drugs

There is no evidence *to date* of hypogammalobulinaemia as a clinical problem in patients treated with non-depleting B-cell medications such as belimumab or atacicept, but numbers of patients treated are much less than with rituximab [28, 29]. No significant difference was noted between belimumab and placebo in development of hypogammaglobulinemia [28]. While reductions in immunoglobulin levels were noted with atacicept, no cases of severe hypogammagloblinaemia (< 3g/L) were noted, and no increase in serious infections [29].

Patients with AIRD have often had previous exposure to other medicines associated with hypogammaglobulinemia, including corticosteroids, cyclophosphamide (as discussed above), gold,

mycophenolate mofetil, alemtuzumab, sulfasalazine and ciclosporin [14]. These drugs may also confound the potential relationship between IgG levels and infection due to effects beyond the B-cell lineage [14].

3.7 The potential role for memory B-cell monitoring

B-cell repopulation following rituximab treatment in patients with AIRD has not been studied systematically over a long-term period. There is evidence to suggest a direct correlation between numbers of switched memory (CD27+ IgM- IgD-) B-cells and risk of disease relapse following rituximab treatment in AAV, but this data awaits confirmation [22]. Disease relapse reported in AAV is common following rituximab cessation, and it is often heralded by B-cell reconstitution [18]. Persistent loss of memory B-cells may be a clue to development and persistence of hypogammaglobulinemia [22].

3.8 Vaccination strategies and performance

EULAR recommendations state that vaccination status should be assessed during the initial work-up of patients with AIRD. The decision to vaccinate patients should be decided on a case by case basis, following evaluation of the risks and benefits in the context of a patient's immunocompetence [30].

EULAR recommend avoiding live attenuated vaccines in immunosuppressed patients with AIRD when possible. Ideally all indicated non-live vaccinations should be administered at least 4 weeks prior to the initiation of BCTT therapy [31]. However this should not delay BCTT in urgent cases. In particular vaccination against influenza, pneumococcus, tetanus toxoid every 10 years and hepatitis B for at-risk populations should be considered [31]. Patients receiving conventional immunosuppressive therapy or undergoing BCTT may have impaired response to vaccination with pneumococcal polysaccharide or novel antigens [18]; testing vaccination responses may be indicated [32]. B-cell recovery may provide a marker to guide revaccination schedules [33]. Influenza and pneumococcal vaccinations are recommended as there is a high level of respiratory tract infections in rituximab treated patients.

Test vaccinations currently are recommended by DoH to evaluate for functional antibody deficiency in secondary hypogammaglobulinemia (utilising polysaccharide vaccines such as unconjugated pneumococcus). However, as there is substantial data showing rituximab impairs protective humoral responses, this may be superfluous in some cases, particularly if there is severe hypogammaglobulinemia. EULAR reported from a systematic review that humoral responses to pneumococcal vaccine were impaired for 28 weeks after treatment with rituximab, and to influenza vaccine for 1-3 months after rituximab [30].

3.9 Health economics

There is limited data regarding health economics of IGRT for secondary hypogammaglobulinemia. Further evaluation in the UK is required. There is more experience and established data for the health economics for IGRT in PID and in some haematological malignancies. There is data on health costs in AAV where hospitalisation more than doubles the annual health costs per patient, to over \$80,000 (2013 US prices) [34].

4. Discussion

In this review, we have assessed the role of IGRT in the management of BCTT-induced secondary hypogammaglobulinemia in AIRD. At present there are few studies focused on BCTT and these are

mostly retrospective cohort studies. The main limitations are the small numbers of such patients receiving IGRT in these studies, and the lack of randomised controlled trials.

The evidence supports pre-existing low IgG levels being a risk factor for developing hypogammaglobulinemia during BCTT, however this should not be a contra-indication to commencing or continuing BCTT. It has not been definitively established that patients with previous cyclophosphamide or other immunosuppressive drug exposure are at a higher risk of developing hypogammaglobulinemia. Independent of the effect of non-rituximab disease treatment, different diseases appear to vary in their susceptibility to low IgG levels after rituximab. The most common diagnosis was AAV in patients receiving IGRT subsequent to BCTT. The explanation for this variability is not yet known. It is recommended that all patients should have serum immunoglobulin measurements prior to commencing BCTT, to establish a baseline and exclude underlying immunodeficiency. These levels should be monitored for long-term changes during follow-up [32].

We consider numerical hypogammaglobulinemia as a low IgG level below the local laboratory reference range. Patients with numerical hypogammaglobulinemia may not be symptomatic and therefore may not require IGRT. Agreement regarding definitions of mild, moderate and severe hypogammaglobulinemia is lacking. Evidence is limited for clear intervention thresholds for IGRT, such as asymptomatic patients with numerical hypogammaglobulinemia.

Currently there is no standardised definition for recurrent infection. However, infections characteristic of hypogammaglobulinemia are typically sino-pulmonary, caused by encapsulated organisms such as pneumococcus [35]. The decision to start IGRT should consider a history of serious, persistent, unusual or recurrent (SPUR) infections. IGRT should be considered in patients with a significant burden of infections accompanied by hypogammaglobulinemia [36]. The role of measurement of baseline specific antibodies and responses to test vaccinations has not been universally agreed upon.

Treatment targets for IGRT would be valuable, as the current evidence is unclear and is largely based on evidence from PID. Guidelines on when to refer a patient to Clinical Immunology during BCTT are needed, especially for complex cases. For example, if a patient is symptomatic without hypogammaglobulinemia or where a patient is asymptomatic but has numerical hypogammaglobulinemia, would referral be indicated by the autoimmune disease physician?

Health economic data for secondary hypogammaglobulinemia in AIRD and patient assessment tools would aid the evaluation of current IGRT practice and improve quality of life outcomes. While BCTT for AIRD can be efficacious, the risk of hypogammaglobulinemia and infections (particularly when pursuing prolonged maintenance therapy) needs balancing against the risk of disease relapse if BCTT is discontinued. In this context IGRT has an important role in the management of (symptomatic) hypogammaglobulinemia [14].

We recognise the limitations of this SLR, due to the sparse data available on the use of IGRT for BCTT associated hypogammaglobulinemia in AIRD. Long-term outcome data and randomised controlled studies from this group of patients are not present in the current literature.

5. Research Agenda

The effect of IGRT in reducing infection frequency and prevention of hospital admissions has been demonstrated in small studies in SID. IGRT initiation appeared to be associated with a reduction in the number of infections in moderate or severe hypogammaglobulinemia in a case series of AAV [14] and in mixed study populations of Haematology and Rheumatology patients [30]. Further research in larger prospective studies is required in AIRD.

BCTT use is likely to increase in AIRD, with a wider range of B-cell agents (including biosimilars). The findings from this review have highlighted areas in need of further research. At present data from PID and haematological malignancies provides guidance, whilst awaiting further studies in AIRD. Research regarding immunoglobulin recovery following BCTT, the safety of continuing BCTT in patients with low or falling IgG, use of memory B-cell panels for monitoring hypogammaglobulinemia development, and long-term prognosis of AIRD patients with hypogammaglobulinemia are needed [8]. Studies of IGRT efficacy and cost-effectiveness in this group of patients are warranted.

Acknowledgments: nil

References

1. Bousfiha AA, Jeddane L, Ailal F, Al Herz W, Conley ME, Cunningham-Rundles C, et al. A phenotypic approach for IUIS PID classification and diagnosis: guidelines for clinicians at the bedside. J Clin Immunol 2013;33:1078–1087.

2. Castigli E, Geha RS. Molecular basis of common variable immunodeficiency. J Allergy Clin Immunol 2006;117:740–746.

3. Duraisingham SS, Buckland MS, Grigoriadou S, Longhurst HJ. Secondary antibody deficiency. Expert Rev Clin Immunol 2014;10:583–591.

4. Herriot R, Sewell WA. Antibody deficiency. J Clin Path 2008;61:994–1000.

5. Rose ME, Lang DM. Evaluating and managing hypogammaglobulinemia. Cleve Clin J Med 2006;73:133-7, 140, 143-4.

6. Li PH, Lau C-S. Secondary antibody deficiency and immunoglobulin replacement. Hong Kong Bulletin on Rheumatic Diseases 2017;17:1-5.

7. Marco H, Smith RM, Jones RB, Guerry M, Catapano F, Burns S, et al., The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease. BMC Musculoskelet Disord 2014;15:178.

8. Roberts DM, Jones RB, Smith RM, Alberici F, Kumaratne DS, Burns S, et al. Rituximab-associated hypogammaglobulinemia: Incidence, predictors and outcomes in patients with multi-system autoimmune disease. J Autoimmun 2015;57:60-65.

9. Boleto G, Avouac J, Wipff J, Forien M, Dougados M, Roux C et al., Predictors of hypogammaglobulinemia during rituximab maintenance therapy in rheumatoid arthritis: A 12-year longitudinal multi-center study, Semin Arthritis Rheum, 2018 Oct;48(2):149-154. doi: 10.1016/j.semarthrit.2018.02.010. Epub 2018 Feb 21.

10. Kronbichler A, Windpessl M, Pieringer H, Jayne DRW, Rituximab for immunologic renal disease: What the nephrologist needs to know, Autoimmun Rev, 2017 Jun;16(6):633-643. doi: 10.1016/j.autrev.2017.04.007. Epub 2017 Apr 13.

11. Kaplan B, Kopyltsova Y, Khokhar A, Lam F, Bonagura V. Rituximab and immune deficiency: case series and review of the literature. J Allergy Clin Immunol: In Practice 2014;2:594–600.

12. Leandro MJ, Edwards JC, Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion, Ann Rheum Dis, 2002 Oct;61(10):883-8.

<u>13. De La Torre I, Leandro MJ, Valor L, Becerra E, Edwards JC, Cambridge G</u>, Total serum immunoglobulin levels in patients with RA after multiple B-cell depletion cycles based on

rituximab: relationship with B-cell kinetics, <u>Rheumatology (Oxford)</u>, 2012 May;51(5):833-40. doi: 10.1093/rheumatology/ker417. Epub 2012 Jan 16.

14. Roberts DM, Jones RB, Smith RM, Alberici F, Kumaratne DS, Burns S, et al. Immunoglobulin G replacement for the treatment of infective complications of rituximab-associated hypogammaglobulinemia in autoimmune disease: a case series. J Autoimmun 2015;57:24-9.

15. Levy R, Mahévas M, Galicier L, Boutboul D, Moroch J, Loustau V et al., Profound symptomatic hypogammaglobulinemia: a rare late complication after rituximab treatment for immune thrombocytopenia. Report of 3 cases and systematic review of the literature, Autoimmun Rev. 2014 Oct;13(10):1055-63. doi: 10.1016/j.autrev.2014.08.036. Epub 2014 Aug 27.

16. Scottish Intercollegiate Guidelines Network, Healthcare Improvement Scotland, 2018, Available at <u>www.sign.ac.uk/checklists-and-notes.html</u> Accessed October 2018.

17. van Vollenhoven RF, Fleischmann RM, Furst DE, Lacey S, Lehane PB, Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years, J Rheumatol. 2015 Oct;42(10):1761-6. doi: 10.3899/jrheum.150051. Epub 2015 Aug 15.

18. Cortazar FB, Pendergraft WF 3rd, Wenger J, Owens CT, Laliberte K, Niles JL. Effect of continuous B cell depletion with rituximab on pathogenic autoantibodies and total IgG levels in antineutrophil cytoplasmic antibody–associated vasculitis. Arthritis Rheum 2017;69:1045–1053.

19. Venhoff N, Effelsberg NM, Salzer U, Warnatz K, Peter HH, Lebrecht D et al., Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides, PLoS One. 2012;7(5):e37626. doi: 10.1371/journal.pone.0037626. Epub 2012 May 21.

20. Besada E, Koldingsnes W, Nossent JC, Serum immunoglobulin levels and risk factors for hypogammaglobulinemia during long-term maintenance therapy with rituximab in patients with granulomatosis with polyangiitis. Rheumatology 2014;53:1818-1824.

21. Gottenberg JE, Ravaud P, Bardin T, Cacoub P, Cantagrel A, Combe B, et al; on behalf of the Investigators of the Auto Immunity and Rituximab registry and the French Society of Rheumatology. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum 2010;62:2625–2632.

22. Venhoff N, Niessen L, Kreuzaler M, Rolink AG, Hassler F, Rizzi M, et al., Reconstitution of the peripheral B lymphocyte compartment in patients with ANCA-associated vasculitides treated with rituximab for relapsing or refractory disease. Autoimmunity 2014;47:401-408.

23. Yates M, Watts RA, Bajema IM, Cid MC, Crestani B, Hauser T, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis 2016;75:1583-1594.

24. Bukhari M, Abernethy R, Deighton C, Ding T, Hyrich K, Lunt M et al. BSR and BHPR guidelines on the use of rituximab in rheumatoid arthritis. Rheumatology 2011;50:2311–2313.

25. Perez EE, Orange JS, Bonilla F, Chinen J, Chinn IK, Dorsey M, et al. Update on the use of immunoglobulin in human disease: A review of evidence. J Allergy Clin Immunol 2017;139(3S):S1-S46.

26. Clinical Guidelines for Immunoglobulin Use (Second Edition), Department of Health, 2011 [Available from: <u>https://www.gov.uk/government/publications/clinical-guidelines-for-immunoglobulin-use-second-edition-update</u>. Accessed October 2018. 27. Lucas M, Lee M, Lortan J, Lopez-Granados E, Misbah S, Chapel H, et al. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol 2010;125:1354-1360.

28.Merrill JT, Wallace DJ, Wax S, Kao A, Fraser PA, Chang P, Isenberg D; ADDRESS II Investigators. Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus: Results of a Twenty-Four-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Phase IIb Study. Arthritis Rheumatol 2018;70:266-276

29.Stohl W, Schwarting A, Okada M, Scheinberg M, Doria A, Hammer AE, et al. Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study. Arthritis Rheumatol 2017;69:1016-1027

30. van Assen S, Elkayam O, Agmon-Levin N, Cervera R, Doran MF, Dougados M, et al. Vaccination in adult patients with auto-immune inflammatory rheumatic diseases: A systematic literature review for the European League Against Rheumatism evidence-based recommendations for vaccination in adult patients with auto-immune inflammatory rheumatic diseases. Autoimmun Rev 2011;10:341-352.

31. Buch MH, Smolen JS, Betteridge N, Breedveld FC, Burmester G, Dorner T, et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2011;70:909e20.

32. Makatsori M, Kiani-Alikhan S, Manson AL, Verma N, Leandro M, Gurugama NP, et al., Hypogammaglobulinemia after rituximab treatment—incidence and outcomes. QJM 2014;107:821-828.

33. Immunisation against infectious disease, The Green Book, Department of Health, 2013, ChapterImmunisation against infectious disease, The Green Book, Department of Health, 2013, Chapter 25.

https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file /660902/Green_book_cover_and_contents.pdf Accessed October 2018

34. Raimundo K, Farr AM, Kim G, Duna G. Clinical and Economic Burden of Antineutrophil Cytoplasmic Antibody-associated Vasculitis in the United States. J Rheumatol 2015;42:2383-2891.

35. Duraisingham SS, Manson A, Grigoriadou S, Buckland M, Tong CY, Longhurst HJ. Immune deficiency: changing spectrum of pathogens. Clin Exp Immunol. 2015;181:267-74.

36. Compagno N, Malipiero G, Cinetto F, Agostini C. Immunoglobulin replacement therapy in secondary hypogammaglobulinemia. Front Immunol 2014;5:626.